Related Experiment Video
Updated: Aug 4, 2025

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
Published on: December 9, 2022
Endothelium-biomarkers for postthrombotic syndrome: a case-control study
Sabrina Ranero1,2, Gonzalo Silveira2,3, Natalia Trias2
1Catedra de Hematologia. Hospital de Clinicas. Facultad de Medicina.
Novel biomarkers, including circulating endothelial cells (CEC), endothelial progenitor cells (EPC), and fractalkine, may help predict and treat postthrombotic syndrome (PTS) after deep venous thrombosis (DVT). Further research into these mediators could lead to new therapeutic targets.
Area of Science:
- Vascular Biology
- Biomarker Discovery
- Thrombosis Research
Background:
- Postthrombotic syndrome (PTS) is a chronic complication following deep venous thrombosis (DVT).
- Understanding PTS pathophysiology and identifying predictive biomarkers are crucial for improved patient outcomes.
- This study investigated novel endothelial biomarkers for PTS in non-acute DVT patients.
Purpose of the Study:
- To identify and analyze novel endothelial biomarkers associated with the development of postthrombotic syndrome (PTS).
- To evaluate the potential of circulating endothelial cells (CEC), endothelial progenitor cells (EPC), and specific plasma proteins as predictors of PTS.
- To explore the correlation between identified biomarkers and the severity of PTS.
Main Methods:
- A case-control study design was employed.
- Patients with confirmed DVT, treated for at least 3 months, were included.
- Plasma levels of ICAM-1, P-selectin, fractalkine, VEGF, CEC, and EPC were quantified using cytometric bead array and flow cytometry.
Main Results:
- PTS patients exhibited significantly higher levels of CEC and EPC compared to controls.
- Elevated plasma fractalkine levels were observed in patients with PTS.
- Fractalkine levels demonstrated a strong positive linear correlation with the Villalta score for PTS severity.
Conclusions:
- Circulating endothelial cells (CEC), endothelial progenitor cells (EPC), and fractalkine are identified as potential novel biomarkers for PTS development.
- These mediators may play a role in the progression and worsening of PTS.
- The findings suggest that CEC, EPC, and fractalkine could represent future therapeutic targets for managing PTS.
More Related Videos
09:19In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Related Concept Videos
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Venous Thrombosis IV: Nursing Management